McLaughlin Gerald W. 4

What Happened
Gerald W. McLaughlin, a director of Allarity Therapeutics, Inc. (ALLR), was granted 45,000 restricted stock units (RSUs) on January 28, 2026. The RSUs were reported as vested in full on the grant date under Allarity’s Amended and Restated 2021 Equity Incentive Plan. The reported acquisition price is $0.00 (typical for RSU awards, which are compensation rather than a purchase).

Key Details

• Transaction date: January 28, 2026 (Form 4 filed May 7, 2026).
• Transaction type/code: A — Award/Grant/Other acquisition (45,000 RSUs).
• Reported price: $0.00 per share (total reported cash outlay $0).
• Vesting: Per footnote, the RSUs vested in full on the grant date.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Filing date (May 7, 2026) is well after the transaction date (Jan 28, 2026); this appears to be a late Form 4 filing.

Context
RSU grants that vest immediately are a form of compensation to insiders and are recorded as an acquisition on Form 4; they do not represent a market purchase or sale. The $0.00 price reflects that these were granted/vested shares rather than bought — it is not a market valuation. Such awards are common for executive/director compensation and do not, by themselves, indicate a buy or sell signal.